Proactive Investors - Run By Investors For Investors

Scancell’s Modi-2 anti-cancer vaccine shows potential in pre-clinical studies

Modi-2 is the second vaccine developed from the Moditope platform after Modi-1, and Scancell thinks each one has the potential to treat different types of cancer
t cells attacking cancer
Both Modi-1 and Modi-2 stimulate production of cancer-killing CD4 T cells

Pre-clinical data has shown that Scancell Holdings PLC’s (LON:SCLP) Modi-2 vaccine has the potential to treat different types of cancer to its forerunner, Modi-1.

Modi-2 is the second vaccine developed from Scancell’s Moditope platform after Modi-1, the lead Moditope vaccine which is due to enter the clinic in 2019.

IN-DEPTH: Scancell part of the new cancer revolution

The two drugs work in slightly different ways, although both stimulate the production of CD4 T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.

Modi-1 will be tested as a treatment for breast and ovarian cancers, as well as sarcoma (tumours found in fat, muscle, bone and tendons) when its clinical trial begins next year.

But Scancell thinks Modi-2 has the potential to address different cancer indications to Modi-1, including tumours which work particularly hard to suppress the immune system.

“We are pleased to be able to provide an update on the progress of our second Moditope vaccine, Modi-2,” said chief scientific officer Lindy Durrant.

“The data clearly demonstrates the potential of homocitrullinated (Modi-2), as well as citrullinated (Modi-1), tumour-associated peptide epitopes to be developed for the treatment of solid cancers.”

Scancell shares rose 0.8% to 7.8p in mid-afternoon trade.

-- Updates for share price --

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use